Jubilant Ingrevia stock surges 7% above 200-Day Moving Average, indicating bullish case. Traders can go long now, accumulate on dips, and target ₹540-545 over next 3-4 weeks. Keep stop-loss at ₹440, trail up to ₹485 & ₹510. Exit long positions at ₹535. Risk of loss in trading.

Stock to buy today: Jubilant Ingrevia (₹476.15)

Khubchandani, in his most recent role, has served as Co-CEO and Whole-time Director of Jubilant Ingrevia. Over his 20-year career at Jubilant Ingrevia, Khubchandani was a strategic business leader, developed high-performing teams, and oversaw solutions and offerings for pharmaceutical, agrochemical,…

PAG-led Sekhmet Pharmaventures announces the hiring of Anil Khubchandani as MD and CEO

Sanjiv Bhasin of IIFL Securities, recommends investing in two specialty chemical companies, Chemplast Sanmar and Jubilant Ingrevia, for a potential 40-50% upside in the next year. Bhasin also praises the Adani Group and believes the long-term story remains robust. He suggests investing in cement com…

Sanjiv Bhasin Portfolio | Chemical Stocks: 2 specialty chemical stocks to go for if you seek 40-50% upside in next one year: Sanjiv Bhasin

Prabhudas Lilladher is bullish on Jubilant Ingrevia has recommended buy rating on the stock with a target price of Rs 715 in its research report dated May 17, 2023.

Buy Jubilant Ingrevia; target of Rs 715: Prabhudas Lilladher

Consolidated net profit fell to 523.1 million rupees ($6.4 million) for the three months ended March 31 from 685.9 million rupees a year earlier, marking the fourth straight quarter of earnings drop

Jubilant Ingrevia Q4 profit slump 24% as supplements faced headwinds

TCS, Dr Reddy’s Lab, Eris Lifesciences, Glenmark Pharma, RVNL, Lemon Tree Hotels, IndiaMart InterMesh, Samvardhana Motherson, Shri Keshav Cement, Quint Digital, Jubilant Ingrevia and Vishvprabha Foods are some of the stocks that are likely to be in action today

stocks in action today

Prabhudas Lilladher is bullish on Jubilant Ingrevia has recommended buy rating on the stock with a target price of Rs 900 in its research report dated February 01, 2023.

Buy Jubilant Ingrevia; target of Rs 900: Prabhudas Lilladher

Stocks to watch out for today: Airtel, Jubilant Ingrevia, City Union Bank, Future Enterprises, VIP Clothing, Shyam Metalics and Energy and more

Stocks in the news: Airtel, Jubilant Ingrevia, City Union Bank, Future Enterprises and more

Jubilant Ingrevia issued Commercial Papers (CPs) of Rs 150 crore on 20 December 2022.

Jubilant Ingrevia issues CPs worth Rs 150 cr

“Jubilant Ingrevia has been forming a ‘Higher Top Higher Bottom’ structure on the daily chart and prices are trading in a ‘Rising Channel’ which indicates a short-term uptrend and post the recent correction,” Ruchit Jain, Lead Research, 5paisa.com, said.

#stocks #stockrecommendation #stockmarketnews #trading #tradingstrategy #stockmarket #stock 

► Subscribe to The Economic Times for the latest video updates. It's free! - https://www.youtube.com/TheEconomicTimes?sub_confirmation=1

► More Videos @ ETTV - https://economictimes.indiatimes.com/TV

► https://EconomicTimes.com

► For business news on the go, download ET app:
https://etapp.onelink.me/tOvY/EconomicTimesApp

Follow ET on:

► Facebook - https://www.facebook.com/EconomicTimes 
► Twitter - https://www.twitter.com/economictimes
► LinkedIn - https://www.linkedin.com/company/economictimes
► Instagram - https://www.instagram.com/the_economic_times
► Flipboard - https://flipboard.com/@economictimes

#news #latestnews #economictimes #ET #TheEconomicTimes #businessnews

Stock Radar: Buy Jubilant Ingrevia for a target of Rs 580-600, says Ruchit Jain

Jubilant Ingrevia shares hit a 52-week low of Rs 401.35 on March 8, 2022. Since then, the stock has gained 37.65% or Rs 151 till date

Jubilant Ingrevia shares rise 37% from 52-week low; how far can they go?

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Jubilant Ingrevia is engaged in the business of integrated life science products.